Survival plots.

<p><b>a. and b.:</b> Disease-free survival and disease-specific survival according to FAS expression; <b>c. and d.:</b> Disease-free survival and disease-specific survival according to FASL expression.</p

Multivariate analysis of the relationship between clinical, pathological tumor features and survival with FAS and FASL expression.

<p>OR – Odds ratio; HR – Hazard ratio; CI – Confidence interval.</p>¥<p>Values adjusted by multivariate logistic regression.</p>§<p>Values adjusted by Cox proportional hazards.</p

Survival plots.

<p><b>a. and b.:</b> Disease-free survival and disease-specific survival according to FAS/FASL profile.</p

Epidemiological, clinical and pathological tumor features and their association with FAS and FASL expression.

¥<p>TNM classification 3^rd edition.</p>*<p>Not available (not considered in the statistical calculations).</p

Epidemiological features.

<p>Epidemiological features.</p

Immunohistochemical.

<p><b>a.</b> Positive FAS expression; <b>b.</b> Positive FASL expression; <b>c.</b> Negative immunostaining. Magnification was 400×.</p

Survival plots.

<p><b>a. and b.</b> Disease-free and disease-specific survivals according to HIF-1alpha expression in lymphoid cells of the peritumoral infiltrate; <b>c. and d.</b>: Disease-free and disease-specific survivals according to HIF-1alpha expression in lymphoid cells of the intratumoral infiltrate.</p

Clinical and pathological features and their relation with HIF-1alpha expression in lymphoid cells of the inflammatory infiltrate; intratumoral and peritumoral.

<p>^a TNM classification (3rd edition) <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0084923#pone.0084923-Deschler1" target="_blank">[17]</a>.</p><p>^b Not available – Not considered in statistical calculations.</p

Immunohistochemistry.

<p><b>a and b.</b> Weak and strong HIF-1alpha expression in peritumoral inflammatory infiltrates; <b>c. and d.</b> Weak and strong HIF-1alpha expression in intratumoral inflammatory infiltrates. Magnification was 400×.</p

HIF-1alpha risk profile and correlation with disease relapse and death.

<p>HIF-1alpha risk profile and correlation with disease relapse and death.</p